Scienmag
OCTOBER 23, 2020
Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch
Drug Discovery World
APRIL 8, 2024
Following this, Benjamin Cravatt, Professor and the Norton Gilula Chair in Biology and Chemistry at The Scripps Research Institute, discussed activity-based protein profiling (ABPP) and its use in discovering drug candidates for cancer-relevant proteins.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
SEPTEMBER 21, 2022
Scientists have discovered a type of breast cancer cell that is highly efficient in invading and colonising distant organs and slow their growth once there to evade therapies. Scientists also found in animal models that these unique cells slow and stop their own growth, keeping them in a dormant state in distant organs such as the lungs.
Drug Discovery World
JULY 5, 2023
A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent? MG: I am responsible for Agilent’s cancer segment.
Drug Discovery World
JANUARY 23, 2023
Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance. Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care.
Drug Discovery World
OCTOBER 27, 2023
With cues from a diverse population of tissue-specific cell types, extracellular matrix proteins, and biomechanical forces, cells grown in organ-chips closely emulate their in vivo counterparts and replicate tissue-level functions. But can organ-chips entirely replace other models? Not yet, according to Ewart.
Drug Discovery World
APRIL 3, 2023
As a business of scientists, we remain passionate about the exciting developments in the industry, from research to precision therapies, and insatiably curious about the new possibilities that can be achieved by overcoming the limits of standard research tools and methods. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.
Expert insights. Personalized for you.
53 
Let's personalize your content